4 quarters tracked · Beat rate 75% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $1.18 | $1.91 | +62.3% | Beat |
| Q4 2025 | 2025-12-31 | $1.92 | $1.48 | -22.9% | Miss |
| Q3 2025 | 2025-09-30 | $1.62 | $2.04 | +26.1% | Beat |
| Q2 2025 | 2025-06-30 | $0.99 | $1.06 | +7.0% | Beat |
Earnings Beat Rate
Neurocrine Biosciences has beaten analyst EPS estimates in 3 of 4 tracked quarters (75% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →